OPEN REVIEW Experimental Molecular Medicine 2015 47 e141 doi101038emm2014114 2015 KSBMB All rights reserved 2092641315 wwwnaturecomemm Understanding molecular mechanisms natural killer cell therapy Suk Ran Yoon123 TaeDon Kim123 Inpyo Choi12 Cancer cells immune closely related inﬂuence Although immune cells suppress cancer cell growth cancer cells evade immune cell attack immune escape mechanisms Natural killer NK cells kill cancer cells secreting perforins granzymes Upon contact cancer cells NK cells form immune synapses deliver lethal hit Mature NK cells differentiated hematopoietic stem cells bone marrow They lymph nodes activated interactions dendritic cells Interleukin15 IL15 key molecule activates mature NK cells The adoptive transfer NK cells treat incurable cancer attractive approach A certain number activated NK cells required adoptive NK cell therapy To prepare NK cells mature NK cells ampliﬁed obtain sufﬁcient numbers NK cells Alternatively NK cells differentiated ampliﬁed hematopoietic stem cells In addition selection donors important achieve maximal efﬁcacy In review discuss overall procedures strategies NK cell therapy cancer Experimental Molecular Medicine 2015 47 e141 doi101038emm2014114 published online 13 February 2015 INTRODUCTION As gain better understanding molecular mechan isms controlling natural killer NK cell activity potential possible application cancer immunotherapy grows increasingly NK cells play key roles innate adaptive immune responses unique NK cell activation mechan isms early host defense viruses tumors performing major roles contactdependent cytotoxicity cytokine production immune modulation Target cell apoptosis primarily mediated perforin Prf1 granzyme B GzmBmediated pathways regulation immune responses mediated secretion cytokines interferonγ tumornecrosis factorα13 Compared T B cells understanding checkpoints developmental stages lead generation cells committed NK cell lineage remain poorly deﬁned The developmental processes drive hema topoietic stem cells HSCs NK cells identiﬁed4 Emerging experimental evidence suggests NK cell differ entiation depends deﬁned cytokines temporal induction transcription factors microRNA miRNAbased gene expression5 Recently research groups developed protocols vitro NK cell differentiation based reconstitution cytokines providing good strategy amplifying NK cells therapeutic applications68 Recent advances understanding manipulation NK cell activation development led hope NK cells harnessed immunotherapy cancers diseases This review provides framework understanding impact NK cell activation developmentdifferentiation clinical implications We summarize sequential activation processes priming immune synapse formation recep tor signaling effector functions manipulation tuning fundamental questions NK cell activity discussed concerning development successful NK cell based therapies In addition NK CELL ACTIVATION Current insights molecular speciﬁcities regulate NK cell functions vivo suggest possible design NK cellbased immunotherapeutic strategies human cancer In section review overall processes including receptor NK cell activation mechanisms 1Immunotherapy Research Center Korea Research Institute Bioscience Biotechnology Daejeon Republic Korea 2Department Functional Genomics Korea University Science Technology Daejeon Republic Korea 3These authors contributed equally work Correspondence Dr I Choi Immunotherapy Research Center Korea Research Institute Bioscience Biotechnology Yuseonggu Daejeon 305806 Republic Korea Email ipchoikribbrekr Received 20 October 2014 revised 17 November 2014 accepted 2 December 2014 2 Development NK cell therapy SR Yoon et al signaling immune synapse formation NK roles discuss possible strategies NK cell targeting human tumors development successful NK cellbased therapies9 Receptor signaling NK cell activation controlled dynamic balance positive negative signals provided main types receptors121011 The receptorsNKG2D NKp46 NKp30 NKp44 activating form killer cell immunoglobulinlike receptor KIR known KIRS CD16provide positive signals ﬁnally triggering cytotoxicity production cytokines Some activating cell surface receptors stimulate protein tyrosine kinasedependent pathways reversible associations transmembrane signaling adaptors These adaptor proteins harbor cytoplasmic immunoreceptor tyrosinebased activation motifs consist consensus aminoacid sequence paired tyrosines leucines YxxI Lx612YxxIL12 These motifs normally located cytoplasmic domains ligandbinding transmembrane recep tors T cell receptor highafﬁnity immunoglo bulin E receptor FcεRI mediate interactions transmembrane receptor complex protein tyrosine kinases required initiate early late signaling events Additional cell surface receptors directly coupled immunoreceptor tyrosinebased activation motifs partici pate NK cell activation These include NKG2D associated DAP10 transmembrane signaling adaptor integrins cytokine receptors9 The discovery NKG2D ligands MICA RAET1 family NKp30 ligand B7H6 suggests receptors recognize molecules rarely present normal cells upregulated infection carcinogenesis Figure 1 characterized intracytoplasmic NK cells express cell surface inhibitory receptors protein tyrosine antagonize activating pathways phosphatases412 The typical inhibitory receptor KIR recog nizes self subsequently provides negative signals ﬁnally suppress NK cell activation inhibition stimulatory signaling pathway The ligand KIR major histocompat ibility complex MHC class I molecules self present normal cells3 These inhibitory cell surface receptors immunoreceptor tyrosinebased inhibition motifs2 present cytoplasmic domains inhibitory receptors After ligand binding intracytoplasmic immunoreceptor tyrosinebased inhibition motifs phosphorylated tyrosine residues recruit lipid tyrosine phosphatases The tyrosine phosphor ylation status signaling components sub strates protein tyrosine kinase protein tyrosine phosphatases key molecules propagation NK cell effector pathways Understanding integration multiple signals central understanding manipulation NK cell effector signaling pathways Figure 1 Cytokines important signals regulating prolifera tion survival activation status effector functions immune In addition NK cell development survival Experimental Molecular Medicine turn cellcell interface decides outcome Figure 1 Natural killer NK cell activation translation therapeutic application The encounter NK cell target cell results adhesion conjugation Immune Synapse The dynamic balance inhibitory activating receptor signaling immune synapse Engagement NK cell activating receptors ITAM kinase tight actin induces phosphorylation lead stable cytoskeleton rearrangements conjugation Activation NK cells primed activated cytokines locally secreted immune cells inducing types immunerelated gene expression including cytokines NK cell effectors noncoding microRNAs miRNAs Sustained stimulatory signaling causes robust actin polymerization polarization MTOC immune synapse Lytic granules containing effectors example GzmB Prf1 transported microtubule tracks subsequent release Prf1 GzmB induce target cell including proinﬂammatory apoptosis Upon activation cytokines cytokines example interferonγ IFNγ secreted immune regulation NK cell functions Major strategies harness NK cell functions cancer Tuning NK cell activity First treatment cytokines promotes NK cell proliferation differentiation activation andor inhibits NK cell suppressors Second manipulating balance stimulatory inhibitory signaling promote NK cell activation use CAR andor adoptive transfer allosteric NK cells In addition strategies focused NK effector activation promoting TRAIL tumornecrosis factor TNF related apoptosisinducing ligand CD178 expression ADCC activation engineered Fc Third strategies enhanced antiinhibitory antibodies speciﬁc negative regulators KIR NKG2A PD1 ADCC antibodydependent cellular cytotoxicity CAR chimeric antigen receptor GzmB granzyme B ITIM ITAM tyrosinebased activation motif immunoreceptor tyrosinebased inhibitory motif KIR killer cell immunoglobulinlike receptor MHC major histocompatibility MTOC microtubuleorganizing center PD1 programmed cell death 1 Prf1 perforin NK cell inhibition NK cell activation Substances act NK cells indicated red text immunoreceptor function require cytokines including interleukin IL2 IL12 IL15 IL18 IL2113 Among IL15 shown play key role NK cell development priming activation based studies IL15 IL15 receptor deﬁcient mice1415 In recent report development innate NK cell memory brief combined activation IL12 IL15 IL18 resulted generation longlived NK cells exhibited enhanced functionality encountered secondary stimulation16 providing new possibility enhancing NK cell responsiveness viral infec tions tumors An improved understanding cellular molecular networks cytokinecytokine receptor signals led resurgence clinical use cytokines sustain andor activate NK cell antitumor potential Immune synapse formation As immune cells majority NK cell effector functions require direct celltocell contact Target cell binding accompanied creation complex structures cellcell interface considered immune synapse1217 This concept ﬁrst proposed DM Davis 1999 missingself recognition inhibitory interactions18 Recent progress contributed characterization types NK cell immunological synapses demonstrated NK cell immune synapses primary sites highly complex regulation NK cell activity occurs919 The NK cell immunological synapse dynamic interface formed NK cell target cell The formation NK cell immunological synapse involves distinct stages initiation contact target cell directed delivery lytic granule contents target cell lysis17 Progression individual stages regulated tight regulation underlies precision NK cells select kill susceptible target cells including virally infected transformed cells tumor cells encounter surveillance body Effector molecules Several killing pathways NK cell cytotoxicity characterized14 First Prf1 GzmBmediated mechan ism demonstrates granzymes serine proteases primarily cytoplasmic granules NK cells Prf1 facilitates delivery Gzms cytosol target cell GzmB bestcharacterized Gzm cleaves procaspases intracellular substrates initiate classical apoptotic pathways Second CD95 FASCD178 FAS ligand pathway leads formation death inducing signaling complex subsequent activation caspases promote apoptotic process CD95 expressing target cell Third antibodydependent cellular cytotoxicity mechanism leukocytes including NK cells express CD16 Fc receptors kill antibodycoated target cells Figure 1 Among cytotoxic effector molecules general bestknown effectors Prf1 GzmB20 The contact NK cell susceptible target cell results conjugation formation immunological synapse The stimulation NK cellactivating receptors ligands Development NK cell therapy SR Yoon et al 3 target cell induces phosphorylation membrane proximal signaling molecules formation signaling complex comprising signaling adapter molecules junction Positive feedback loops generated causing signal ampliﬁcation sustained signaling induce robust actin polymerization synapse zone polarization microtubuleorganizing center lytic granules immu nological synapse Prf1 GzmB lytic granules subsequently exocytosed target cell membrane12 MicroRNAs NK cell biology The miRNAs abundant class endogenous small noncoding RNAs 1922 nucleotides generated sequen tial processing primary miRNA transcripts ribonu cleases Drosha nucleus Dicer1 cytoplasm Mature miRNAs associate 3 untranslated regions speciﬁc target mRNAs downregulate gene expression targeting mRNAs translational suppression mRNA degradation Recently involvement miRNAs immune responses development NK cells hematopoietic stem cells widely investigated gain loss function speciﬁc miRNAs disruption molecules involved biogenesisactivity miRNAs example Argonaute Drosha Dicer21 The miRNAs regulate fundamental NK cell processes development prolifera shown tion cytotoxicity cytokine production Table 1 The growing evidence impact miRNAs NK cell biology suggests modulating endogenous levels speciﬁc miRNA NK cells represents potential strategy immunotherapy522 Tuning NK cell activation Upon tuning threshold NK cell activation NK cells exert effector functions transformed self Table 1 Selected microRNA roles NK cell biology MicroRNA Target genes Cell type miRNA expression miR27a miR150 miR223 miR378 30e miR155 Mature NK cells Developing NK cells Human Prf1 GzmB6 Mouse cMyb123 Prf1 human mouse124 Mature NK cells Human mouse IFNγ123 Mature NK cells Mouse GzmB125 Mature NK cells Human Prf1 GzmB126 Mature NK cells Human mouse IFNγ127 Mature NK cells SHIP1 human21 Mature NK cells Noxa SOCS1 mouse128 Mature NK cells Human mouse IFNγ129 Mature NK cells Human mouse IFNγ130 Mature NK cells Mature NK cells Mature NK cells miR181 miR29 miR132 212 200a STAT4 human131 DAP12 human132 miR183 Abbreviations DAP12 DNAX activation protein 12 kDa GzmB granzyme B IFNγ interferonγ miRNA microRNA NK natural killer Prf1 perforin SHIP1 SH2 Src homology 2containing inositol phosphatase1 SOCS1 suppressor cytokine signaling 1 STAT4 signal transducer activator transcription 4 Experimental Molecular Medicine 4 Development NK cell therapy SR Yoon et al sustaining tolerance normal self Recent progress standing NK cell biology brings approach realm clinical trials An emerging idea threshold NK cell reactivity tuned interactions environment As shown lower panel Figure 1 strategies harness NK cell functions cancer therapy summarized categories23 1 enhancing receptor signaling manipulating balance inhibitory activating NK receptors NK cell effector functions 2 blocking negative regulators use monoclonal antibodies 3 treatment involving cytokines promote NK cell prolifera tion viability activity NK CELL GENERATION NK cell development NK cells known originate hematopoietic precursor cells bone marrow BM24 However hema topoietic precursor cells lymph nodes secondary lymphoid tissues8 maternal decida25 fetus2627 Nevertheless NK cell thymus liver development primarily occurs BM microenvironment In general NK cells derived CD34 HSCs discrete stages development precursor NK pNK immature NK iNK mature NK characterized sequential acquisition surface receptors effector function2829 HSCs rise different hematopoietic lineages common lymphoid progenitors common myeloid progenitors Common lymphoid progenitors differentiate NKT progenitors potential develop T andor NK cells Following NKT cells differentiate pNK iNK ﬁnally mature NK830 Recently Grzywacz et al31 demonstrated NK cells derived myeloid precursors common myeloid progenitors CD33CD13 population The transition NKT pNK cells deﬁned expression IL215Rβ CD122 receptor26 Along IL2Rβ expres sion IL7 stem cell factor Flt3L FMSlike tyrosine kinase 3 ligand commit HSCs NK lineage32 In humans pNKs characterized CD34CD122CD56 phenotype pNK cells respond IL15 critical factor ﬁnal maturation NK cells As cells differentiate pNK iNK cells expression Flt3 IL7Rα decreases expres sion IL2Rβ CD2 2B4 CD244 increases3334 The iNK cells identiﬁed expression CD161 supported population CD3CD56CD161 cells vitro NK cell differentiation CD34 Lin umbilical cord blood UCB cells35 Although IL15 known indispensable NK cell development3637 generation pNKs HSCs likely IL15independent mechanism38 IL15 speciﬁc receptor IL15R mediate NK cell development committed pNKs promote differentiation iNK cells39 The ﬁnal maturation NK cells characterized acquisition activating inhibitory receptor expression The activating receptor NKp44 ﬁrst NK cell receptor expressed early stage NK cell maturation The NKp46 NKp30 NKG2D DNAM1 activating receptors acquired later stage The ﬁrst inhibitory receptor expressed vitro NK cell differentiation CD94 NKG2A8 The NK cell maturation process includes MHC class involves recognition selfMHC class I molecules cognate inhibitory receptors KIRs4041 Further steps NK cell maturation required acquisition cytolytic machinery perforin granzymes42 Iinduced NK education licensing Factors involved NK differentiation Although developmental pathways NK cells relatively unclear compared T B lymphocytes process NK cell differentiation coordinated mechanism involves cytokines surface receptors transcription factors The BM microenvironment major source cytokines initiates facilitates NK differentiation Within BM maturation NK cells4344 stromal cells assist suggesting BM stroma critical factors differentiation NK cells Although intact BM microenvironment essential NK differentiation stromal cell requirement replaced partially earlyacting cytokines including stem cell factor Flt3L IL 73245 induce CD122 responsiveness recep tors pNKs Transcription factors involved controlling NK cell differentiation process The Ets family example PU1 Ets1 Ikaros family example Ikaros Helios Aiolos4648 essential generation NK cells vivo speciﬁcation maintenance pNKs The inhibitors DNA binding Id proteins including ID2 ID349 E4BP450 regulate cellfate decisions early stage NK development In addition reported VDUP1 vitamin D3 upregulated protein 1 stress response gene regulates NK differentiation controlling CD122 expression IL15 responsiveness51 Transcription factors including Gata352 IRF253 Tox654 involved ﬁnal maturation NK cells absence leads incomplete development functional NK cells imma ture phenotypes NK cells The acquisition mature NK cell function related presence Eomesodermin EOMES T cellspeciﬁc Tbox transcription factor Tbet 55 induce expression cytolytic machinery example perforin granzymes interferonγ65456 Production NK cells vitro Recently NK cell immunotherapy developing rapidly Achieving NK cell immunotherapy cancer requires adequate number NK cells NK cell purity functional activity Human NK cells obtained directly indirectly sources peripheral blood PB UCB BM embryonic stem cells hESCs induced pluripotent stem cells iPSCs29 Experimental Molecular Medicine Development NK cell therapy SR Yoon et al 5 NK cell generation efﬁciency PB UCB NK cells directly isolated PB UCB expanded short long periods time vitro subsequently infused cancer treatment Several protocols developed expansion PB NK cells clinical studies57 Puriﬁed PB NK cells expanded feeder cells autologous irradiated feeder cells thirdparty EpsteinBarr virustransformed lymphoblastoid B cell lines5859 In addition genetically modiﬁed K562 cells including K562 cells trans duced IL2160 K562 cells double transduced IL15 41BB CD137 ligand K562mb1541BBL61 feeder cells NK coculture systems The main advantage methods immediate availability cells longterm expansion vitro compared novo production NK cells However prolonged exposure NK cells cytokines vitro induces cell exhaustion lead low functional activity NK cells Moreover complete removal residual viable tumor feeder ﬁnal cell products required NK cell immunotherapy Alternatively NK cells selectively isolated UCB considered good source cell therapy Positively isolated cord blood NK cells cultured feeder layer mesenchymal stromal cells combination IL2 IL15 Flt3L IL3 achieved 60fold expansion62 However low initial numbers NK cells UCB feasible approach generating cell numbers required application NK cell therapy To overcome obstacles directly isolating NK cells fresh samples NK cells generated CD34 HSCs vitro Generating NK cells CD34 stem cells advantageous stem cells isolated frozen Furthermore NK cells manipulated process differentiation HSCs vitro63 NK cell generation UCB CD34 stem cells It shown NK cells originated CD34 stem cell compartment vivo64 Therefore NK cells generated vitro CD34 HSCs BM3345 UCB6566 different combinations cytokines BM stromal cells culture media supplemented animal human sera However culture systems contain components animal origin fail produce signiﬁcant numbers NK cells Kao et al67 demonstrated fetal bovine serum UCB CD34 cells differentiated NK cells purity 4060 ﬁnally reaching 300fold expansion Using complete medium containing human serum fetal bovine serum cytokines including IL15 IL21 methylprednisolone shown induce rapid differentiation CD34 HSCs NK cells attaining 10fold expansion NK cells68 In addition Spanholtz et al6970 developed novel cell culture technique ex vivo expansion differentiation NK cells UCB CD34 cells absence feeder cells serumfree culture medium coupled mixture heparin cytokines mimic extracellular matrix BM microenvironment In protocol 1010 CD34 cellderived NK cells Tcell contamination generated However transplantation study nonobese diabeticsevere combined immunodeﬁciency mice receiving human HSCs demonstrated NK cell differentiation UCB CD34 cells slower efﬁcient NK cell differentiation BM CD34 cells66 Furthermore study demonstrated UCB CD34 cells differentiated NK cells lacking expression KIRs including CD158a KIR2DL1 CD158b KIR2DL2DL3 NKB166 Coculture feeder layer EL081D2 shown UCB CD34 derived NK cells acquired coordinated NK cell receptors represent cytotoxic CD56 cells71 NK cell generation BM mobilized PB Because NK cells developed BM microenvironment vivo BM rich source CD34 stem cells NK cells mature properties successfully generated sorted CD34 cells BM2845 The main disadvantages working BM stem cells limitations cell number painful procedure harvesting cells To facilitate harvesting stem cells alternatively mobilized granulocyte colonystimulating factor72 Giuliani et al73 generated differentiated NK cells mobilized PB stem cells study effect membranebound IL15 In 2010 developed protocol generating NK cells isolated CD34 cells mobilized PB clinical trials performed allogeneic NK cell transfer haploidentical hematopoietic stem cell transplantation HSCT74 Recently developed novel protocol generation NK cells T celldepleted mononuclear cells mobilized PB allows shorter time period differentiation generation increased NK cell numbers compared earlier protocol75 NK cell generation hESCs Because hESCs iPSCs rise CD34 HSCs serve source NK cell differentiation76 Knorr et al77 engineered CD34 cells hESCs iPSCs expressed chimeric antigen receptors CARs speciﬁc tumorassociated antigens immu notherapy However generation NK cells hESCs iPSCs experimental phase generation CD34 HSCs hESCs iPSCs hESC iPSC based NK cell therapies requires optimization7779 In summary methods NK cell production vitro application immunotherapy shown Figure 2 NK CELL THERAPY Because ability recognize lyse broad range tumor cells prior priming NK cells emerged promising candidates cancer therapy Because NK cells primarily blood NK therapy successful hematopoietic malignancies leukemias NK cell immunotherapy achieved activating endogenous NK cell response administering NK stimulants exogenous NK cells HSCT adoptive cell transfer Several strategies NK cell immunotherapies human cancer proposed10 Experimental Molecular Medicine 6 Development NK cell therapy SR Yoon et al Figure 2 Production natural killer NK cells vitro immunotherapy Human NK cells obtained sources peripheral blood PB umbilical cord blood UCB bone marrow BM mobilized PB mPB embryonic stem cells ESCs NK cells isolated PB UCB expanded In addition NK cells generated CD34 hematopoietic stem cells HSCs UCB BM mPB ESCs CD34 HSCs differentiated CD56 mature NK cells mNK CD122 precursor NK cells pNK Finally mNK cells armed effector functions infused patient adoptive immunotherapy Activation endogenous NK cell response Nonfunctional NK cells frequently cancer patients exogenous NK activators enhance endogenous NK response tumors Cytokines including IL2 IL12 IL15 IL18 IL21 type I interferons activate endogenous NK cells directly indirectly8081 The administration IL2 shown activate expand NK cell populations cancer patients8283 IL2 treatment limited severe effects To reduce effects IL2 combination therapy IL2 IL12 IL21 proposed84 IL15 promising candidate activating NK cells IL15 indispensable NK cell maturation When combined chemotherapy administration IL15 potentiated antitumor effects85 In addition immunomodulators shown increase activity NK cells tumor cells For example thalidomide lenalidomide increased number peripheral blood NK cells activated NK function myeloma cells mediated stimulation IL2 production T cells8688 Similarly adjuvant intravesical bacillus Calmette Guerin89 CpG oligodeoxynucleotides40 enhance antitumor activity superﬁcial bladder cancer nonHodgkins lymphoma respectively Bortezomib protea inhibitor applied increase suscept ibility tumor cells upregulation death receptors trigger cytolysis NK cells90 NK cell adoptive immunotherapy Adoptive immunotherapy refers introduction ex vivo manipulated cells patients clinical applications NK cells isolated expanded produced vitro transferred autologous allogeneic setting The ﬁrst trial involving adoptive transfer NK cells antitumor therapy performed Rosenberg91 combination ex vivo expanded autologous lymphokineactivated killer cells induced 20 exogenous IL2 However response including partial complete responses rate similar antitumor effect achieved administration highdose IL2 alone92 trial Unlike autologous cell transfers allogeneic adoptive cell transfers beneﬁt mismatched KIRKIR ligands host donor NK cells therapies run great risk graftversushost disease GVHD cause severe damage host tissues Ruggeri et al93 ﬁrst identiﬁed correlation donor KIR host KIR ligand expression occurrence tumor relapse Com pared KIRmatched transplants KIR mismatches donor NK cells express KIRs ligand patient produced graftversustumor GVT effects acute myeloid leukemia AML patients In 2005 Miller et al94 performed combined therapy haploidentical NK infusion IL2 administration AML cell patients nontransplantation setting This study demon strated safety efﬁcacy adoptively transferred human NK cells 26 AML patients achieving complete remission An infusion haploidentical allogeneic NK cells applied patients poor prognosis Hodgkins lymphoma95 solid tumors melanoma renal cancer96 Another approach adoptive immunotherapy NK lymphomaderived cell line NK92 proposed limited data exist efﬁcacy approach97 To date adoptive transfer therapy NK cells applied combination allogeneic stem cell transplantation donor lymphocyte infusion DLI Experimental Molecular Medicine Hematopoietic stem cell transplantation HSCT therapy applied hematological malignancies classiﬁed autologous allogeneic depending source donor cells Currently allogeneic stem cell transplantation unrelated sibling donors hematological malignancies AML acute lymphoblast leukemia6393 Allogeneic HSCT requires human leukocyte antigen HLAmismatched donor BM cells harvested infused patient Because T cell receptors highly individualized sensitive nonself presentation recipient antigenpresenting cells dendritic cells aberrantly activate donorderived T cells In recipient activated T cells mediate severe damage characteristic GVHD Conversely donorderived T cells recognize kill residual tumor cells recipient referred GVT graftversusleukemia effect The current strategies improve outcome allogeneic HSCT cancer therapy focused minimizing harmful GVDH reactions maximizing beneﬁcial GVT effects To reduce risk GVHD T cells required depleted donor grafts eliminating GVHD expense inhibiting GVT effects98 Unlike T cells NK cells demonstrated enhance GVT effects implication GVHD99 Allogeneic NK cells stem cell transplantation Unfortunately patients relapse HSCT To prevent relapses patients HSCT DLI induce potent GVT effect DLI cause T cellinduced GVHD To minimize risk GVHD T celldepleted DLI applied The introduction T celldepleted donor lymphocytes containing alloreactive NK cells improved survival patients enhancing graftversusleukemia effect reducing GVHD100 DLI puriﬁed donor NK cells shown facilitate engraftment induce GVT effects contributing GVHD haploidentical HSCT101 GVT effects mediated donorderived NK cells NK cells developed donor hematopoietic stem cells102103 Because NK cells kill normal missingself targets respond target cells expressing foreign MHC class I alleles NK cell alloreactivity beneﬁcially utilized HSCT A prerequisite NK cell alloreactivity recipient lack KIR ligands present donor recipients MHC class I allele match KIR donorderived NK cells Taking advantage NK cell allor eactivity allogeneic NK cells combination HSCT suppress GVHD promote graftversusleukemia effect Allogeneic NK cells HLAmismatched donor decrease GVHD killing recipient antigenpresenting cells example dendritic cells initiate GVHD produce graftversusleukemia effect killing residual cancer cells recipient Furthermore allogeneic NK cells directly kill recipients T cells leading improved engraftment Development NK cell therapy SR Yoon et al 7 Velardis group93 initially demonstrated donorversus recipient NK cell alloactivity prevent leukemia relapse AML patients increasing risk GVHD haploidentical HSCT It shown infusion allogeneic KIR ligandmismatched NK cells improved survival rate reduced relapse rate haploidentical HSCT AML patients93104 Other studies conﬁrmed beneﬁcial effect KIRligand mismatch relapse rate survival recipient105106 Although allogeneic NK cell products optimized Tcell depletion NK cell expansion107 clinical production NK cells lacking Recently group developed protocol allogeneic NK cell production Tcell contamination clinical trials Using protocol allogeneic NK cells derived HLAmismatched donors transferred AML patients haploidentical trans plantation resulting reduced relapse rates increased survival rates patients7475 standardized protocols Other clinical strategies NK cell therapy Several approaches developed enhance effect NK cell immunotherapy selectively blocking activating NK receptors108 Blocking CD94NKG2A inhibi tory KIRs NK cells reduce NK inhibitory signal leading enhanced NK activity109 upregulating expression activating receptors NKG2D NK cells ligands ULBPs MICAB tumor cells increase NK activating signal110 Histone deacetylase inhibitors111112 heat shock 90 inhibitors113 shown upregulate expression NKG2D ligands MICA MICB tumor cells rendering tumor cells susceptible NK cellmediated cytotoxicity Treatment drugs melphalan etoposide doxorubicin induce DNA damage responses increased susceptibility myeloma cells NK cells upregulating NK activating ligands DNAX accessory molecule1 DNAM1 ligand NKG2D ligand113 Antibodies block inhibitory receptors mimic missing selfenvironment augment NK cellmediated killing Recently human mono clonal antibody 17F9 prevents signaling KIR2DL1 KIR2DL2 KIR2DL3 developed increase NK cell mediated cytotoxicity tumors expressing HLAC114115 In addition bortezomib proteasome inhibitor shown increase NK function reducing expression MHC class I surface myeloma cells116 NK cell effector functions mediated antibody dependent cellular cytotoxicity117 Because NK cells execute antibodydependent cellular cytotoxicity CD16 FCRγIII receptor surface treatment anti body trigger effector functions NK cells tumor targets For example CD20 lymphoma administration CD20 antibody rituximab induced antibodydependent cellular cytotoxicity antibodycoated target cells binding CD16 receptor surface NK cells118119 Similarly bispeciﬁc antibodies CD16 NK cells Experimental Molecular Medicine 8 Development NK cell therapy SR Yoon et al Figure 3 From hematopoietic stem cells HSCs clinical application Natural killer NK cells differentiated HSCs For efﬁcient NK cell therapy step NK cell preparation important NK cell differentiation activation genetically modiﬁed NK cells chimeric antigen receptor CARNK major strategies generation potent NK cell therapy CD30 nonHodgkins lymphoma promoted NK cell recog nition cytolysis tumor cells120 extend ﬁeld application enhance availability ﬁght diseases future Genetic engineering NK cells important manipulating enhancing therapeutic potential Because T cells successfully genetically engineered express CAR CD19 similar strategies developed NK cells NK cells transduced disialoganglioside GD2recognizing CAR applied enhance cytotoxi city neuroblastoma121 Engineering NK cells CARs speciﬁc CD19 CD20 proposed treatment leukemias lymphomas respectively54122 CONCLUSION NK cells diverse functions regulating innate adaptive immune responses These properties derived molecular characteristics NK cells They express different surface receptors recognize target cells appropriate ligands surface In addition NK cells secrete cytokines soluble factors regulate immune cells T cells dendritic cells These functional properties NK cells applicable clinical treatment groups achieving limited success To explore NK cell therapy effectively need understand NK cell biology function NK cells differentiated HSCs At steps NK cell differentiation activation genetic modiﬁcation exam ple CARNK cells serve critical target successful clinical applications Figure 3 In preparation NK cells NK cells properly activated NK cell subsets manipulated depending type disease NK cells cytolytic activity required treatment cancer NK cells secrete interferons beneﬁcial treatment viral infections Several issues considered develop ment successful NK cellbased immunotherapy Among NK cell preparation includes purity expansion NK cells criteria donor selection KIR genotypes alloreactive subset sizes The optimal doses timing administration NK cells deter mined Additional factors consideration include opti mization conditioning recipients enhancement NK cell function tumor cell susceptibility NK cell therapy combined immunothera pies including cytotoxic T lymphocyte therapy antibody therapy Understanding NK cell properties functions Experimental Molecular Medicine CONFLICT OF INTEREST The authors declare conﬂict ACKNOWLEDGEMENTS This work supported grants GRL project FGM1401223 Ministry Science ICT Future Planning KRIBB Research Initiative Program Korean Health Technology RD Project A121934 Basic Science Research Program National Research Foundation Korea RBM0261413 RBM0271413 1 2 Vivier E Ugolini S Blaise D Chabannon C Brossay L Targeting natural killer cells natural killer T cells cancer Nat Rev Immunol 2012 12 239252 Vivier E Ugolini S Natural killer cells basic research treatments Front Immunol 2011 2 18 3 Romagne F Vivier E Natural killer cellbased therapies F1000 Med Rep 2011 3 9 4 NarniMancinelli E Ugolini S Vivier E Tuning threshold natural 5 killer cell responses Curr Opin Immunol 2013 25 5358 Leong JW Sullivan RP Fehniger TA microRNA management NKcell developmental functional programs Eur J Immunol 2014 44 28622868 7 6 Kim TD Lee SU Yun S Sun HN Lee SH Kim JW et al Human microRNA27a targets Prf1 GzmB expression regulate NKcell cytotoxicity Blood 2011 118 54765486 Yun S Lee SH Yoon SR Kim MS Piao ZH Myung PK et al TOX regulates differentiation human natural killer cells hemato poietic stem cells vitro Immunol Lett 2011 136 2936 Freud AG Caligiuri MA Human natural killer cell development Immunol Rev 2006 214 5672 8 9 Malhotra A Shanker A NK cells immune crosstalk therapeutic implications Immunotherapy 2011 3 11431166 10 Ljunggren HG Malmberg KJ Prospects use NK cells Immunol 2007 7 immunotherapy human cancer Nat Rev 329339 11 Vivier E Nunes JA Vely F Natural killer cell signaling pathways Science 2004 306 15171519 12 Krzewski K Strominger JL The killers kiss functions NK cell immunological synapses Curr Opin Cell Biol 2008 20 597605 13 Romee R Leong JW Fehniger TA Utilizing cytokines functionenable human NK cells immunotherapy cancer Scientiﬁca Cairo 2014 2014 205796 14 Fehniger TA Caligiuri MA Interleukin 15 biology relevance human disease Blood 2001 97 1432 15 Lucas M Schachterle W Oberle K Aichele P Diefenbach A Dendritic cells prime natural killer cells transpresenting interleukin 15 Immu nity 2007 26 503517 Development NK cell therapy SR Yoon et al 9 16 Cooper MA Elliott JM Keyel PA Yang L Carrero JA Yokoyama WM Cytokineinduced memorylike natural killer cells Proc Natl Acad Sci USA 2009 106 19151919 17 RodaNavarro P Reyburn HT Intercellular protein transfer NK cell immune synapse mechanisms physiological signiﬁcance FASEB J 2007 21 16361646 18 Davis DM Chiu I Fassett M Cohen GB Mandelboim O Strominger JL The human natural killer cell immune synapse Proc Natl Acad Sci USA 1999 96 1506215067 19 Orange JS Formation function lytic NKcell immunological synapse Nat Rev Immunol 2008 8 713725 20 Cao X Cai SF Fehniger TA Song J Collins LI PiwnicaWorms DR et al Granzyme B perforin important regulatory T cellmediated suppression tumor clearance Immunity 2007 27 635646 21 Sullivan RP Leong JW Schneider SE Keppel CR Germino E French AR et al MicroRNAdeﬁcient NK cells exhibit decreased survival enhanced function J Immunol 2012 188 30193030 22 Sullivan RP Leong JW Fehniger TA MicroRNA regulation natural killer cells Front Immunol 2013 4 44 NK cell precursors peripheral NK cells vivo J Immunol 2005 174 12131221 39 Roychowdhury S Blaser BW Freud AG Katz K Bhatt D Ferketich AK et al IL15 IL2 rapidly induces lethal xenogeneic graftversus host disease Blood 2005 106 24332435 40 Anfossi N Andre P Guia S Falk CS Roetynck S Stewart CA et al Human NK cell education inhibitory receptors MHC class I Immunity 2006 25 331342 41 Yokoyama WM Kim S Licensing natural killer cells selfmajor histocompatibility complex class I Immunol Rev 2006 214 143154 42 Montaldo E Vacca P Moretta L Mingari MC Understanding human NK cell differentiation clues improving haploidentical hematopoietic stem cell transplantation Immunol Lett 2013 155 25 43 van den Brink MR Boggs SS Herberman RB Hiserodt JC The generation natural killer NK cells NK precursor cells rat longterm bone marrow cultures J Exp Med 1990 172 303313 44 Ogasawara K Hida S Azimi N Tagaya Y Sato T YokochiFukuda T et al Requirement IRF1 microenvironment supporting development natural killer cells Nature 1998 391 700703 23 Terme M Ullrich E Delahaye NF Chaput N Zitvogel L Natural killer cell directed therapies moving unexpected results successful strate gies Nat Immunol 2008 9 486494 45 Mrozek E Anderson P Caligiuri MA Role interleukin15 development human CD56 natural killer cells CD34 hemato poietic progenitor cells Blood 1996 87 26322640 24 Colucci F Caligiuri MA Di Santo JP What natural killer Nat Rev Immunol 2003 3 413425 25 Vacca P Vitale C Montaldo E Conte R Cantoni C Fulcheri E et al CD34 hematopoietic precursors present human decidua differenti ate natural killer cells interaction stromal cells Proc Natl Acad Sci USA 2011 108 24022407 26 Ikawa T Kawamoto H Fujimoto S Katsura Y Commitment common T natural killer NK progenitors unipotent T NK progenitors murine fetal thymus revealed single progenitor assay J Exp Med 1999 190 16171626 27 Phillips JH Hori T Nagler A Bhat N Spits H Lanier LL Ontogeny human natural killer NK cells fetal NK cells mediate cytolytic function express cytoplasmic CD3 epsilondelta proteins J Exp Med 1992 175 10551066 28 Miller JS Alley KA McGlave P Differentiation natural killer NK cells human primitive marrow progenitors stromabased longterm culture identiﬁcation CD347 NK progenitor Blood 1994 83 25942601 29 Luevano M Madrigal A Saudemont A Generation natural killer cells hematopoietic stem cells vitro immunotherapy Cell Mol Immunol 2012 9 310320 30 Blom B Spits H Development human lymphoid cells Annu Rev Immunol 2006 24 287320 31 Grzywacz B Kataria N Kataria N Blazar BR Miller JS Verneris MR Natural killercell differentiation myeloid progenitors Blood 2011 117 35483558 32 Williams NS Klem J Puzanov IJ Sivakumar PV Schatzle JD Bennett M et al Natural killer cell differentiation insights knockout transgenic mouse models vitro systems Immunol Rev 1998 165 4761 33 Yu H Fehniger TA Fuchshuber P Thiel KS Vivier E Carson WE et al Flt3 ligand promotes generation distinct CD34 human natural killer cell progenitor responds interleukin15 Blood 1998 92 36473657 34 Sivori S Falco M Marcenaro E Parolini S Biassoni R Bottino C et al Early expression triggering receptors regulatory role 2B4 human natural killer cell precursors undergoing vitro differentiation Proc Natl Acad Sci USA 2002 99 45264531 35 Lanier LL Chang C Phillips JH Human NKRP1A A disulﬁdelinked homodimer Ctype lectin superfamily expressed subset NK T lymphocytes J Immunol 1994 153 24172428 36 Carson WE Giri JG Lindemann MJ Linett ML Ahdieh M Paxton R et al Interleukin IL 15 novel cytokine activates human natural killer cells components IL2 receptor J Exp Med 1994 180 13951403 37 Cooper MA Bush JE Fehniger TA VanDeusen JB Waite RE Liu Y et al In vivo evidence dependence interleukin 15 survival natural killer cells Blood 2002 100 36333638 38 Vosshenrich CA Ranson T Samson SI Corcuff E Colucci F Rosmaraki EE et al Roles common cytokine receptor gammachain dependent cytokines generation differentiation maturation 46 Warren LA Rothenberg EV Regulatory coding lymphoid lineage choice hematopoietic transcription factors Curr Opin Immunol 2003 15 166175 47 Colucci F Samson SI DeKoter RP Lantz O Singh H Di Santo JP Differential requirement transcription factor PU1 generation natural killer cells versus B T cells Blood 2001 97 26252632 48 Boggs SS Trevisan M Patrene K Geogopoulos K Lack natural killer cell precursors fetal liver Ikaros knockout mutant mice Nat Immun 1998 16 137145 49 Spits H Couwenberg F Bakker AQ Weijer K Uittenbogaart CH Id2 Id3 inhibit development CD34 stem cells predendritic cell pre DC2 preDC1 Evidence lymphoid origin preDC2 J Exp Med 2000 192 17751784 50 Kamizono S Duncan GS Seidel MG Morimoto A Hamada K Grosveld G et al Nﬁl3E4bp4 required development maturation NK cells vivo J Exp Med 2009 206 29772986 51 Lee KN Kang HS Jeon JH Kim EM Yoon SR Song H et al VDUP1 required development natural killer cells Immunity 2005 22 195208 52 Samson SI Richard O Tavian M Ranson T Vosshenrich CA Colucci F et al GATA3 promotes maturation IFNgamma production liver speciﬁc homing NK cells Immunity 2003 19 701711 53 Lohoff M Duncan GS Ferrick D Mittrucker HW Bischof S Prechtl S et al Deﬁciency transcription factor interferon regulatory factor IRF2 leads severely compromised development natural killer T helper type 1 cells J Exp Med 2000 192 325336 54 Aliahmad P la Torre B Kaye J Shared dependence DNA binding factor TOX development lymphoid tissueinducer cell NK cell lineages Nat Immunol 2010 11 945952 55 Townsend MJ Weinmann AS Matsuda JL Salomon R Farnham PJ Biron CA et al Tbet regulates terminal maturation homeostasis NK Valpha14i NKT cells Immunity 2004 20 477494 56 Gascoyne DM Long E VeigaFernandes H Boer J Williams O Seddon B et al The basic leucine zipper transcription factor E4BP4 essential natural killer cell development Nat Immunol 2009 10 11181124 57 Koepsell SA Miller JS McKenna DH Jr Natural killer cells review manufacturing clinical utility Transfusion 2013 53 404410 58 Siegler U MeyerMonard S Jorger S Stern M Tichelli A Gratwohl A et al Good manufacturing practicecompliant cell sorting largescale expansion single KIRpositive alloreactive human natural killer cells multiple infusions leukemia patients Cytotherapy 2010 12 750763 59 Berg M Lundqvist A McCoy P Jr Samsel L Fan Y Tawab A et al Clinicalgrade ex vivoexpanded human natural killer cells upregulate activating receptors death receptor ligands enhanced cytolytic activity tumor cells Cytotherapy 2009 11 341355 60 Gong W Xiao W Hu M Weng X Qian L Pan X et al Ex vivo expansion natural killer cells high cytotoxicity K562 cells modiﬁed express major histocompatibility complex class I chainrelated protein A 41BB ligand interleukin15 Tissue Antigens 2010 76 467475 Experimental Molecular Medicine 10 Development NK cell therapy SR Yoon et al 61 Fujisaki H Kakuda H Shimasaki N Imai C Ma J Lockey T et al Expansion highly cytotoxic human natural killer cells cancer cell therapy Cancer Res 2009 69 40104017 84 Weiss JM Subleski JJ Wigginton JM Wiltrout RH Immunotherapy cancer IL12based cytokine combinations Expert Opin Biol Ther 2007 7 17051721 62 Boissel L Tuncer HH Betancur M Wolfberg A Klingemann H Umbilical cord mesenchymal stem cells increase expansion cord blood natural killer cells Biol Blood Marrow Transplant 2008 14 10311038 63 Shlomchik WD Couzens MS Tang CB McNiff J Robert ME Liu J et al Prevention graft versus host disease inactivation host antigen presenting cells Science 1999 285 412415 64 Di Santo JP Natural killer cell developmental pathways question balance Annu Rev Immunol 2006 24 257286 65 Carayol G Robin C Bourhis JH BennaceurGriscelli A Chouaib S Coulombel L et al NK cells differentiated bone marrow cord blood peripheral blood stem cells exhibit similar phenotype functions Eur J Immunol 1998 28 19912002 66 Kalberer CP Siegler U WodnarFilipowicz A Human NK cell development NODSCID mice receiving grafts cord blood CD34 cells Blood 2003 102 127135 67 Kao IT Yao CL Kong ZL Wu ML Chuang TL Hwang SM Generation natural killer cells serumfree expanded human umbilical cord blood CD34 cells Stem Cells Dev 2007 16 10431051 68 Vitale C Cottalasso F Montaldo E Moretta L Mingari MC Methylpredni solone induces preferential rapid differentiation CD34 cord blood precursors NK cells Int Immunol 2008 20 565575 69 Spanholtz J Tordoir M Eissens D Preijers F van der Meer A Joosten I et al High logscale expansion functional human natural killer cells umbilical cord blood CD34positive cells adoptive cancer immunotherapy PLoS One 2010 5 e9221 70 Spanholtz J Preijers F Tordoir M Trilsbeek C Paardekooper J Witte T et al Clinicalgrade generation active NK cells cord blood hematopoietic progenitor cells immunotherapy closedsystem culture process PLoS One 2011 6 e20740 71 Grzywacz B Kataria N Sikora M Oostendorp RA Dzierzak EA Blazar BR et al Coordinated acquisition inhibitory activating receptors functional properties developing human natural killer cells Blood 2006 108 38243833 72 Petit I SzyperKravitz M Nagler A Lahav M Peled A Habler L et al G CSF induces stem cell mobilization decreasing bone marrow SDF1 upregulating CXCR4 Nat Immunol 2002 3 687694 73 Giuliani M GironMichel J Negrini S Vacca P Durali D Caignard A et al Generation novel regulatory NK cell subset peripheral blood CD34 progenitors promoted membranebound IL15 PLoS One 2008 3 e2241 74 Yoon SR Lee YS Yang SH Ahn KH Lee JH Lee JH et al Generation donor natural killer cells CD34 progenitor cells sub sequent infusion HLAmismatched allogeneic hematopoietic cell transplantation feasibility study Bone Marrow Transplant 2010 45 10381046 75 Choi I Yoon SR Park SY Kim H Jung SJ Jang YJ et al Donorderived natural killer cells infused human leukocyte antigenhaploidentical hematopoietic cell transplantation doseescalation study Biol Blood Marrow Transplant 2014 20 696704 76 Kaufman DS Hanson ET Lewis RL Auerbach R Thomson JA Hemato poietic colonyforming cells derived human embryonic stem cells Proc Natl Acad Sci USA 2001 98 1071610721 77 Knorr DA Kaufman DS Pluripotent stem cellderived natural killer cells cancer therapy Transl Res 2010 156 147154 78 Kaufman DS Toward clinical therapies hematopoietic cells derived human pluripotent stem cells Blood 2009 114 35133523 79 Woll PS Grzywacz B Tian X Marcus RK Knorr DA Verneris MR et al Human embryonic stem cells differentiate homogeneous population natural killer cells potent vivo antitumor activity Blood 2009 113 60946101 80 Smyth MJ Cretney E Kershaw MH Hayakawa Y Cytokines cancer immunity immunotherapy Immunol Rev 2004 202 275293 81 Becknell B Caligiuri MA Interleukin2 interleukin15 roles human natural killer cells Adv Immunol 2005 86 209239 85 Jakobisiak M Golab J Lasek W Interleukin 15 promising candidate immunotherapy Cytokine Growth Factor Rev 2011 22 tumor 99108 86 Hayashi T Hideshima T Akiyama M Podar K Yasui H Raje N et al Molecular mechanisms immunomodulatory drugs activate natural killer cells clinical application Br J Haematol 2005 128 192203 87 Tai YT Li XF Catley L Coffey R Breitkreutz I Bae J et al Immunomo dulatory drug lenalidomide CC5013 IMiD3 augments antiCD40 SGN40induced cytotoxicity human multiple myeloma clinical impli cations Cancer Res 2005 65 1171211720 88 Hsu AK Quach H Tai T Prince HM Harrison SJ Trapani JA et al The immunostimulatory effect lenalidomide NKcell function pro foundly inhibited concurrent dexamethasone therapy Blood 2011 117 16051613 89 Brandau S Riemensberger J Jacobsen M Kemp D Zhao W Zhao X et al NK cells essential effective BCG immunotherapy Int J Cancer 2001 92 697702 90 Ames E Hallett WH Murphy WJ Sensitization human breast cancer cells natural killer cellmediated cytotoxicity proteasome inhibition Clin Exp Immunol 2009 155 504513 91 Rosenberg S Lymphokineactivated killer cells new approach immunotherapy cancer J Natl Cancer Inst 1985 75 595603 92 Rosenberg SA Lotze MT Muul LM Chang AE Avis FP Leitman S et al A progress report treatment 157 patients advanced cancer lymphokineactivated killer cells interleukin2 highdose interleukin2 N Engl J Med 1987 316 889897 93 Ruggeri L Capanni M Urbani E Perruccio K Shlomchik WD Tosti A et al Effectiveness donor natural killer cell alloreactivity mismatched hematopoietic transplants Science 2002 295 20972100 94 Miller JS Soignier Y PanoskaltsisMortari A McNearney SA Yun GH Fautsch SK et al Successful adoptive transfer vivo expansion human haploidentical NK cells patients cancer Blood 2005 105 30513057 95 Bachanova V Burns LJ McKenna DH Curtsinger J PanoskaltsisMortari refractory A Lindgren BR et al Allogeneic natural killer cells lymphoma Cancer Immunol Immunother 2010 59 17391744 96 Geller MA Cooley S Judson PL Ghebre R Carson LF Argenta PA et al A phase II study allogeneic natural killer cell therapy treat patients recurrent ovarian breast cancer Cytotherapy 2011 13 98107 97 Arai S Meagher R Swearingen M Myint H Rich E Martinson J et al Infusion allogeneic cell line NK92 patients advanced renal trial Cytotherapy 2008 10 cell cancer melanoma phase I 625632 98 Welniak LA Blazar BR Murphy WJ Immunobiology allogeneic hematopoietic stem cell transplantation Annu Rev Immunol 2007 25 139170 99 Barao I Murphy WJ The immunobiology natural killer cells bone rejection Biol Blood Marrow Transplant 2003 9 marrow allograft 727741 100 Soiffer RJ Alyea EP Hochberg E Wu C Canning C Parikh B et al Randomized trial CD8 Tcell depletion prevention graft versushost disease associated donor lymphocyte infusion Biol Blood Marrow Transplant 2002 8 625632 101 Passweg JR Tichelli A MeyerMonard S Heim D Stern M Kuhne T et al Puriﬁed donor NKlymphocyte infusion consolidate engraftment transplantation Leukemia 2004 18 haploidentical 18351838 stem cell 102 Ruggeri L Mancusi A Burchielli E Aversa F Martelli MF Velardi A Natural killer cell alloreactivity haploidentical hematopoietic trans plantation Cytotherapy 2006 8 554558 103 Ruggeri L Mancusi A Capanni M Urbani E Carotti A Aloisi T et al Donor natural killer cell allorecognition missing self haploidentical hematopoietic transplantation acute myeloid leukemia challenging predictive value Blood 2007 110 433440 82 Farag SS Caligiuri MA Cytokine modulation innate immune treatment leukemia lymphoma Adv Pharmacol 2004 51 295318 104 Ruggeri L Mancusi A Perruccio K Burchielli E Martelli MF Velardi A Natural killer cell alloreactivity leukemia therapy J Immunother 2005 28 175182 83 Rosenberg SA Interleukin2 development immunotherapy treatment patients cancer Cancer J Sci Am 2000 6Suppl 1 S2S7 105 Giebel S Locatelli F Lamparelli T Velardi A Davies S Frumento G et al Survival advantage KIR ligand incompatibility hematopoietic stem cell transplantation unrelated donors Blood 2003 102 814819 Experimental Molecular Medicine 106 Miller JS Cooley S Parham P Farag SS Verneris MR McQueen KL et al Missing KIR ligands associated relapse increased graft versushost disease GVHD following unrelated donor allogeneic HCT Blood 2007 109 50585061 107 Koehl U Brehm C Huenecke S Zimmermann SY Kloess S Bremm M et al Clinical grade puriﬁcation expansion NK cell products optimized manufacturing protocol Front Oncol 2013 3 118 108 Sentman CL Barber MA Barber A Zhang T NK cell receptors tools cancer immunotherapy Adv Cancer Res 2006 95 249292 109 Long EO Barber DF Burshtyn DN Faure M Peterson M Rajagopalan S et al Inhibition natural killer cell activation signals killer cell Immunol Rev 2001 181 immunoglobulinlike receptors CD158 223233 110 Sutherland CL Rabinovich B Chalupny NJ Brawand P Miller R Cosman D ULBPs human ligands NKG2D receptor stimulate tumor immunity enhancement IL15 Blood 2006 108 13131319 111 Skov S Rieneck K Bovin LF Skak K Tomra S Michelsen BK et al Histone deacetylase inhibitors new class immunosuppressors targeting novel signal pathway essential CD154 expression Blood 2003 101 14301438 112 Diermayr S Himmelreich H Durovic B MathysSchneeberger A Siegler U Langenkamp U et al NKG2D ligand expression AML increases response HDAC inhibitor valproic acid contributes allorecogni tion NKcell lines single KIRHLA class I speciﬁcities Blood 2008 111 14281436 113 Fionda C Soriani A Malgarini G Iannitto ML Santoni A Cippitelli M Heat shock protein90 inhibitors increase MHC class Irelated chain A B ligand expression multiple myeloma cells ability trigger NK cell degranulation J Immunol 2009 183 43854394 114 Romagne F Andre P Spee P Zahn S Anfossi N Gauthier L et al Preclinical characterization 17F9 novel human antiKIR receptor therapeutic antibody augments natural killermediated killing tumor cells Blood 2009 114 26672677 115 Benson DM Jr Bakan CE Zhang S Collins SM Liang J Srivastava S et al IPH2101 novel antiinhibitory KIR antibody lenalidomide combine enhance natural killer cell versus multiple myeloma effect Blood 2011 118 63876391 116 Shi J Tricot GJ Garg TK Malaviarachchi PA Szmania SM Kellum RE et al Bortezomib downregulates cellsurface expression HLA class I enhances natural killer cellmediated lysis myeloma Blood 2008 111 13091317 117 Weiner GJ Rituximab mechanism action Semin Hematol 2010 47 115123 Development NK cell therapy SR Yoon et al 11 ADCClike activity tumour cells neuroectodermal origin J Cell Mol Med 2012 16 569581 122 Muller T Uherek C Maki G Chow KU Schimpf A Klingemann HG et al Expression CD20speciﬁc chimeric antigen receptor enhances cytotoxic activity NK cells overcomes NKresistance lymphoma leukemia cells Cancer Immunol Immunother 2008 57 411423 123 Bezman NA Chakraborty T Bender T Lanier LL miR150 regulates development NK iNKT cells J Exp Med 2011 208 27172731 124 Kim N Kim M Yun S Doh J Greenberg PD Kim TD et al MicroRNA150 regulates cytotoxicity natural killers targeting perforin1 J Allergy Clin Immunol 2014 134 195203 125 Fehniger TA Wylie T Germino E Leong JW Magrini VJ Koul S et al Nextgeneration sequencing identiﬁes natural killer cell microRNA transcriptome Genome Res 2010 20 15901604 126 Wang P Gu Y Zhang Q Han Y Hou J Lin L et al Identiﬁcation resting type reveals microRNA378 microRNA30e negative regulators NK cell cytotoxicity J Immunol 2012 189 211221 IFNactivated human NK cell miRNomes I 127 Trotta R Chen L Ciarlariello D Josyula S Mao C Costinean S et al miR155 regulates IFNgamma production natural killer cells Blood 2012 119 34783485 128 Zawislak CL Beaulieu AM Loeb GB Karo J Canner D Bezman NA et al Stagespeciﬁc regulation natural killer cell homeostasis response viral infection microRNA155 Proc Natl Acad Sci USA 2013 110 69676972 129 Cichocki F Felices M McCullar V Presnell SR AlAttar A Lutz CT et al Cutting edge microRNA181 promotes human NK cell development regulating Notch signaling J Immunol 2011 187 61716175 130 Ma F Xu S Liu X Zhang Q Xu X Liu M et al The microRNA miR29 controls innate adaptive immune responses intracellular bacterial Immunol 2011 12 infection targeting interferongamma Nat 861869 131 Huang Y Lei Y Zhang H Hou L Zhang M Dayton AI MicroRNA regulation STAT4 protein expression rapid sensitive modulation IL12 signaling human natural killer cells Blood 2011 118 67936802 132 Donatelli SS Zhou JM Gilvary DL Eksioglu EA Chen X Cress WD et al TGFbetainducible microRNA183 silences tumorassociated natural killer cells Proc Natl Acad Sci USA 2014 111 42034208 118 DallOzzo S Tartas S Paintaud G Cartron G Colombat P Bardos P et al inﬂuence Rituximabdependent cytotoxicity natural killer cells FCGR3A polymorphism concentrationeffect relationship Cancer Res 2004 64 46644669 119 Marcus R Hagenbeek A The therapeutic use rituximab non Hodgkins lymphoma Eur J Haematol Suppl 2007514 120 Hartmann F Renner C Jung W da Costa L Tembrink S Held G et al AntiCD16CD30 bispeciﬁc antibody treatment Hodgkins disease role infusion schedule costimulation cytokines Clin Cancer Res 2001 7 18731881 121 Esser R Muller T Stefes D Kloess S Seidel D Gillies SD et al NK cells engineered express GD2 speciﬁc antigen receptor display builtin This work licensed Creative Commons AttributionNonCommercialNoDerivs 30 Un ported License The images party material article included articles Creative Commons license indicated credit line material included Creative Commons license users need obtain permission license holder reproduce material To view copy license visit httpcreativecommonsorglicensesbyncnd30 Experimental Molecular Medicine